Terumo Interventional Systems Targets Growth With New Focus on U.S. Urology
April 1, 2013, Marks Start of Company's Direct Distribution and Product
Support of GLIDEWIRE® Hydrophilic Coated Guidewires
SOMERSET, N.J., Feb. 19, 2013
SOMERSET, N.J., Feb. 19, 2013 /PRNewswire/ --Terumo Interventional Systems, a
business unit of Terumo Medical Corporation, today announced the launch of a
new, dedicated group focused on direct sales, marketing, support and
distribution of key products to the urological specialty beginning April 1,
The move is part of the company's commitment to strengthening a direct
relationship with urologists nationwide that currently use its market-leading
GLIDEWIRE® Hydrophilic Guidewire family of products. GLIDEWIRE® guidewires
have captured 94 percent of the Hydrophilic guidewire market and are used in
about one-third of all minimally invasive urological procedures in the U.S.
GLIDEWIRE® guidewires are valued for consistent performance and fast, reliable
access management. This new strategy marks the end of a distribution agreement
of GLIDEWIRE® guidewire products to U.S. urology customers between Boston
Scientific Corporation and Terumo Interventional Systems.
"Terumo Interventional Systems is extremely excited about taking our urology
business direct and we are committed to meeting the growing demands of this
important customer base," said James Rushworth, President, Terumo
Interventional Systems and Onset Medical Corporation. "Combined with our
recent acquisition of Onset Medical, we are poised to offer innovative access
systems to the urology specialty and intend to leverage world-class technology
with our existing robust distribution, supply, and service capabilities to
forge strong physician relationships. Terumo Interventional Systems plans to
introduce a steady stream of devices inspired by clinical performance,
economic advantages, and improved quality of life for patients."
About the Urology Market
According to market research by Millennium Research Group, Inc., the expanding
U.S. urological device market is expected to reach $2.3 billion by 2016. Each
year, approximately 685,000 patients undergo kidney stone management
procedures and the number is expected to steadily increase as more patients
and physicians opt for minimally invasive treatments.
Terumo Interventional Systems has already begun notifying urology customers of
the transition and is providing assistance to ensure uninterrupted product
supply, service, and support.
For additional information about Terumo Interventional Systems and its
products, visit www.terumois.comor contact Robert Murphy, Jitsu Public
Relations, at (908) 276-0777 or firstname.lastname@example.org.
Terumo Interventional Systems
Terumo Interventional Systems (TIS) is a strategic business unit of Terumo
Medical Corporation. As a market leader in entry site management and lesion
access, TIS is committed to pursuing unique technologies designed to enhance
treatment of coronary and peripheral endovascular diseases as well as driving
strategic initiatives focused on Critical Limb Ischemia, Complex Coronary
Intervention and Transradial Access.
TIS directly markets a full line of guidewires, catheters, introducer sheaths,
guiding sheaths and embolization products for use in a multitude of different
Terumo Medical Corporation
Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation
(TMC) develops, manufactures, and markets a complete, solutions-based
portfolio of high-quality medical devices used in a broad range of
applications for numerous areas of the healthcare industry. TMC is comprised
of two business divisions: Terumo Interventional Systems and Terumo Medical
Products. The company places a premium on providing customers with world-class
products, training and education programs that drive clear economic value,
better clinical outcomes and improved Quality of Life for patients.
Tokyo-based Terumo Corporation is one of the world's leading medical device
$5 billion in sales and operations in more than 160 nations. Founded in 1921,
the company develops, manufactures, and distributes world-class medical
devices including products for use in cardiothoracic surgery, interventional
procedures, and transfusion medicine; the company also manufactures a broad
array of syringe and hypodermic needle products for hospital and physician
office use. Terumo contributes to society by providing valued products and
services to the healthcare market and by responding to the needs of healthcare
providers and the people they serve.
Terumo Corporation's shares are listed on the first section of the Tokyo Stock
Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a
component of the Nikkei 225, Japan's leading stock index.
SOURCE Terumo Interventional Systems
Contact: Robert Murphy, Jitsu Public Relations, Inc., +1-908-276-0777,
Press spacebar to pause and continue. Press esc to stop.